![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Fast Track to Immutep’s Eftilagimod Alpha Combo for NSCLC
FDA Grants Fast Track to Immutep’s Eftilagimod Alpha Combo for NSCLC
The FDA has granted a Fast Track designation to Immutep’s eftilagimod alpha in combination with pembrolizumab for treatment of first-line nonsmall-cell lung cancer (NSCLC).
Eftilagimod alpha targets LAG-3, a gene that codes a protein that is involved in the regulation of the immune system. It activates both the innate and adaptive immune system to target solid tumors.
The investigational drug offers a chemotherapy-free option for patients with NSCLC, the company said.
The drug has also received Fast Track status for the treatment of patients with first-line recurrent or metastatic head and neck squamous cell carcinoma.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct